Mizuho lowered the firm’s price target on Immunocore to $72 from $74 and keeps a Buy rating on the shares post the Q3 report. The analyst remains positive ahead of the PRAME data in first half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMCR:
- Immunocore reports Q3 EPS 4c, consensus (33c)
- Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
- Roku upgraded, Amazon initiated: Wall Street’s top analyst calls
- Immunocore initiated with an Overweight at Cantor Fitzgerald
- Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
